Gene

FGFR3

fibroblast growth factor receptor 3

Explore in graph →CI-GENE-00001926HGNC:3690 ENSG00000068078 NCBI 2261 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (214)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 151–200 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 S249C19
(oncogenic)	Transitional Cell Carcinoma	Oncogenic	D	Supports Oncogenicity	3	accepted	EID8855 Compared to controls (empty vector, FGFR3 wildtype, and S249C-Kinase dead cell lines), stable expression of S249C in NIH-3T3 cells resulted in a transformed spindle-like morphology, a 3-fold prolifera…

Cohorts

Alteration frequency by cohort (100)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved100 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Clin Cancer Res 2023) bladder_msk_2023	unmapped	Ssm	443	526

Literature

Linked publications (36)

25 per page, newest first.

pubmedPublishedShowing 26–36 of 36 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System.
· Structure · 2018 · PMID 29478821 · validated civic_curation pubmed
Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
· Mol Cell Biol · 1996 · PMID 8754806 · validated civic_curation pubmed
A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
· J Biol Chem · 2017 · PMID 27927983 · validated civic_curation pubmed
Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
· Hum Mol Genet · 2005 · PMID 15843401

FGFR3 G370C + FGFR3 R248C + FGFR3 S249C + FGFR3 Y373C1
Erdafitinib	Bladder Carcinoma	Predictive	A	Supports Sensitivity Response	4	rejected	EID11259 In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic

FGFR3 G370C + FGFR3 R248C + FGFR3 S249C + FGFR3 Y373C1

Erdafitinib

Bladder Carcinoma

Predictive

Supports Sensitivity Response

rejected

EID11259

In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

FGFR3 V555L2
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	2	submitted	EID12883 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic
Infigratinib	Transitional Cell Carcinoma	Predictive	C	Supports Resistance	3	submitted	EID6405 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC	civic

FGFR3 V555M6
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	accepted	EID12988 Purified recombinant FGFR3 kinase domain protein harboring the V555M substitution exhibited increased in vitro kinase activity compared with wild-type FGFR3. Both autophosphorylation and peptide subst… (full text at CIViC) PMID 26992226 · Patani et al., 2016 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	accepted	EID12989 Purified recombinant FGFR3 kinase domain protein harboring the V555M gatekeeper substitution exhibited increased in vitro kinase activity toward a peptide substrate and increased catalytic efficiency … (full text at CIViC) PMID 26097890 · Bunney et al., 2015 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	4	accepted	EID12990 NIH3T3 cells stably expressing FGFR3 V555M did not exhibit increased cell proliferation, anchorage-independent growth, or morphological transformation compared with cells expressing wild-type FGFR3, w… (full text at CIViC) PMID 26097890 · Bunney et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	1	submitted	EID12882 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic
Infigratinib	Transitional Cell Carcinoma	Predictive	C	Supports Resistance	3	submitted	EID6406 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC	civic
AZ12908010 + Fexagratinib + PD173074Substitutes	Myeloid Neoplasm	Predictive	D	Supports Resistance	2	accepted	EID6408 Preclinical study of FGFR Inhibitors AZ12908010, PD173074 and AZD4547 in cancer cell lines. Cell lines with aberrant FGFR signalling were more sensitive to FGFR Inhibition. Sequencing of a myeloma cel… (full text at CIViC) PMID 22869148 · Chell et al., 2013 · Open in CIViC	civic

FGFR3 Fusion5
(diagnostic)	Thanatophoric DysplasiaUNRESOLVED	Diagnostic	B	Supports Positive	3	submitted	EID7224 Various human skeletal disorders are thought to be caused by mutations in fibroblast growth factor receptor 3 (FGFR3). These result in chronic FGFR3 hyperactivation and inhibition of bone growth. One … (full text at CIViC) PMID 12009017 · Adar et al., 2002 · Open in CIViC	civic
Erdafitinib	Transitional Cell Carcinoma	Predictive	A	Supports Sensitivity Response	4	submitted	EID7262 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic
〃	Bladder Carcinoma	Predictive	A	Supports Sensitivity Response	4	submitted	EID11258 In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic
〃	Transitional Cell Carcinoma	Predictive	A	Supports Sensitivity Response	3	submitted	EID7424 In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic
〃	Bladder Urothelial Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID10405 Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 6 patients with… (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic